You are using an older browser version. Please use a supported version for the best MSN experience.

Glenmark gets USFDA nod for generic skin ointment

LiveMint logoLiveMint 23-08-2017 PTI

New Delhi: Glenmark Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for generic Triamcinolone Acetonide ointment used for treating skin inflammation.

Glenmark Pharmaceuticals Inc USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Triamcinolone Acetonide ointment USP, 0.1%, the company said in a statement. The product is generic version of Mylan Pharmaceuticals Inc’s Kenalog ointment in the same strength, it added.

As per IMS Health sales data for the 12-month period ending June 2017, the Kenalog ointment 0.1% and all available therapeutic equivalents achieved annual sales of around $26.3 million, Glenmark Pharmaceuticals said.

The company’s current portfolio consists of 122 products authorised for distribution in the US market and 64 Abbreviated New Drug Applications pending approval with the USFDA, it added.

Shares of Glenmark Pharmaceuticals were trading at Rs596.60 per scrip in the afternoon trade on the Bombay Stock Exchange (BSE), down 0.80% from the previous close.

More From LiveMint

image beaconimage beaconimage beacon